FDA Approved: XARELTO — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for XARELTO (rivaroxaban) filed by Janssen Pharmaceuticals, resulting in labeling changes to the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

SUPPL AP for XARELTO (RIVAROXABAN)